Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2026eJHaemOpen Access

A Real‐World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B‐Cell Lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LBL. Elizabeth BuddeCity Of Hope National Medical CenterAOAdam J. OlszewskiBrown UniversityBHBei HuLevine Cancer Institute

Discussion

Loading...

Member takes

Implication

Retrospective observational study finds moderate response and survival with R-GemOx in relapsed or refractory large B-cell lymphoma, indicating greater clinical benefit in second-line therapy.

Key Points

  • To characterize real-world treatment patterns and clinical outcomes among patients receiving rituximab, gemcitabine, and oxaliplatin (R-GemOx) for relapsed or refractory large B-cell lymphoma in US clinical practice.
  • Retrospective observational study utilizing the nationwide US Flatiron Health electronic health record database covering patients treated between 2011 and 2023.
  • Identified N=281 patients with relapsed or refractory large B-cell lymphoma who received R-GemOx in the second or later line of therapy, with 66.2% treated in community oncology centers.
  • The overall response rate was 45.4% (95% CI: 38.1–52.9) and the complete response rate was 22.2% (95% CI: 16.4–28.8).
  • Median progression-free survival was 2.8 months (95% CI: 2.6–3.7) and median overall survival was 12.7 months (95% CI: 10.6–17.1).
  • Patients treated in the second line had higher complete response rates (26.3% vs. 17.4%) and longer median overall survival (19.6 vs. 10.0 months) compared to those treated in later lines.

Cite This Study

Budde et al. (2026) studied this question.

synapsesocial.com/papers/6a8147fadc834c04ade1adb4https://doi.org/10.1002/jha2.70351
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.2024 · 3 citations
  2. 2Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification2014 · 5,746 citations
  3. 3Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial2026 · 1 citations
  4. 4Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting2024 · 6 citations
  5. 5Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐ GemOx : A Multicenter Cohort Study2025 · 12 citations